“Vigil has made great progress in the first half of this year as we continue to advance our pipeline of novel candidates for indications with strong genetic links to microglial dysfunction,” said Ivana Magovevi-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. “With the recent strategic investment from Sanofi and our clinical program updates that support an encouraging regulatory pathway for iluzanebart in ALSP and the continued development of VG-3927 for the potential treatment of AD, we believe that we are well-positioned to execute on our strategy to bring these potentially transformative therapies to patients and their families.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIGL:
- Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
- Vigil Neuroscience publishes new data on CSF1R gene variants
- Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer’s Association International Conference (AAIC)
- Vigil Neuroscience’s Promising Phase 1 Trial and Alzheimer’s Focus
- Vigil Neuroscience announces interim data from ongoing Phase 1 trial on VG-3927